Form 4: Biote Corp. CEO Teresa Sue Weber Acquires 777,083 Shares Through Employee Stock Option
SEC Form 4
Biote Corp.'s CEO, Teresa Sue Weber, reports acquiring 777,083 shares through an employee stock option on April 1, 2024.
Summary
- Teresa Sue Weber, CEO of Biote Corp., filed a Form 4 on April 3, 2024, reporting a transaction.
- On April 1, 2024, Weber acquired 777,083 shares of Biote Corp. through an employee stock option with an exercise price of $5.72.
- The option vests over time, with 25% vesting on April 1, 2025, and the remaining shares vesting in 36 equal monthly installments, contingent on continuous service.
- Following the reported transaction, Weber directly owns 2,669,663 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is neither overtly positive nor negative.
Positives
- The acquisition of shares by the CEO could be seen as a positive signal, indicating confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedule of the stock options implies a multi-year commitment from the CEO.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates changes in the CEO's beneficial ownership of Biote Corp. stock.
Comparison to Industry Standards
- Stock option grants are a common form of executive compensation in publicly traded companies, particularly in the biotechnology and pharmaceutical sectors.
- The vesting schedule described is fairly standard, aligning executive incentives with long-term company performance.
- Comparable companies in the biotech space, such as Amgen or Gilead Sciences, also utilize stock options as part of their executive compensation packages.
Stakeholder Impact
- Shareholders may view the CEO's increased stake in the company positively, as it aligns her interests with theirs.
- Employees may see the stock option grant as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 04/01/2024 | Date of the employee stock option transaction. |
| 04/01/2025 | 25% of the shares subject to the option vest. |
| 03/31/2034 | Expiration date of the employee stock option. |
| 04/03/2024 | Date the Form 4 was signed. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.